Stanley Druckenmiller, founder of the Duquesne Family Office, recently closed his positions in two top-performing AI stocks, Nvidia and Palantir Technologies, and increased his investment in Eli Lilly by 52%. He now owns approximately 94,830 shares of Eli Lilly, valued at about $73 million, which constitutes 2.6% of his portfolio.
Druckenmiller sold Nvidia shares after a remarkable 700% increase from late 2022 to late 2023. Nvidia became the top performer in the Dow Jones Industrial Average for 2024, marking significant gains for Druckenmiller. Meanwhile, Palantir Technologies saw a 340% increase last year before Druckenmiller exited his position.
Analysts project that the weight loss drug market, in which Eli Lilly’s products play a crucial role, could reach $95 billion annually by 2030. This growth potential, particularly with new drug developments, positions Lilly as a company to watch in the pharmaceutical sector.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
